FDA Cites Vanda for Misleading Website

Drug Industry Daily
A A
In a rare warning letter from the FDA’s Office of Prescription Drug Promotion (OPDP), Vanda Pharmaceuticals was cited for failing to include any risk information on the product page of its website.

To View This Article:

Login

Subscribe To Drug Industry Daily